Sponsors (22)
The bill strengthens and modernizes support for cord blood and stem cell transplant infrastructure to improve patient access and transplant matching, at the cost of higher authorized federal spending and potential administrative burdens — and those benefits depend on future appropriations.
Patients needing bone marrow, stem cell, or cord blood transplants (including those with chronic conditions) are likely to see improved access because the bill increases authorized funding for the program and aims to expand/modernize the national cord blood inventory.
Hospitals and transplant centers will have more predictable federal support and clearer statutory guidance for registry, matching, and obtaining matched cord blood units, aiding planning and operations.
A modernized and clarified national cord blood inventory could improve match rates and reduce wait times for transplants, potentially improving clinical outcomes for recipients.
Taxpayers face higher federal costs because the bill raises authorized annual funding and could increase costs for collection, storage, or purchase of cord blood units if implemented without offsets.
The bill only increases authorization levels (it does not appropriate funds), so if Congress does not provide matching appropriations the authorized increases may not materialize into actual program funding or benefits.
Cord-blood banks and nonprofit organizations may incur new compliance and operational burdens if the bill imposes additional inventory standards or reporting requirements.
Based on analysis of 3 sections of legislative text.
Extends and slightly increases authorized funding for the federal transplant program and replaces the statute governing cord blood inventory.
Introduced September 4, 2025 by Christopher Henry Smith · Last progress September 4, 2025
Authorizes continued federal funding for the federal C.W. Bill Young Cell Transplantation Program and makes a modest increase in annual authorized funding beginning in FY2027; it also replaces statutory language relating to the program's cord blood inventory. The bill preserves existing authorized funding levels through FY2026, adds higher authorized amounts for FY2027–FY2031, and contains a substantive but unspecified revision to the law governing cord blood inventory requirements or policy.